PubMed:32412509 JSON TXT

Annnotations TAB JSON ListView MergeView

LitCovid-PD-FMA-UBERON

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T1","span":{"begin":1163,"end":1171},"obj":"Body_part"},{"id":"T2","span":{"begin":1451,"end":1460},"obj":"Body_part"},{"id":"T3","span":{"begin":1491,"end":1504},"obj":"Body_part"},{"id":"T4","span":{"begin":1491,"end":1502},"obj":"Body_part"}],"attributes":[{"id":"A1","pred":"fma_id","subj":"T1","obj":"http://purl.org/sig/ont/fma/fma84050"},{"id":"A2","pred":"fma_id","subj":"T2","obj":"http://purl.org/sig/ont/fma/fma84050"},{"id":"A3","pred":"fma_id","subj":"T3","obj":"http://purl.org/sig/ont/fma/fma264829"},{"id":"A4","pred":"fma_id","subj":"T4","obj":"http://purl.org/sig/ont/fma/fma86578"}],"text":"COVID-19 Comes 40 Years After AIDS - Any Lesson?\nThe pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has hit health-care systems and societies in an unprecedented manner. In 1981, the first cases of AIDS were reported and wide diagnostic testing helped to characterize high-risk groups and the global burden of the epidemic. With Coronavirus Disease (COVID)-19, everything has happened too fast and both cases and fatalities are huge but still uncertain in most places. Diagnostic testing of active and past SARS-CoV-2 infections needs to expand rapidly, ideally using rapid tests. COVID-19 deaths are highly concentrated in the elderly population, with a large proportion of fatalities being \"with\" rather than \"by\" SARS-CoV-2 infection. They are often the result of inadequate health care due to overwhelming demands. To date, there is no specific therapy for SARS-CoV-2 infection. Several antivirals are being tested clinically, including remdesivir, at this time the most promising. For others such as lopinavir/ritonavir, neither significant virological nor clinical benefit has been shown. Given the characteristic pulmonary cytokine storm underlying the pathogenic mechanism of severe COVID-19 pneumonia and acute respiratory distress, antiinflammatory agents are being investigated. The benefit of orticosteroids, hydroxychloroquine, etc., is limited. Monoclonal antibodies targeting different pro-inflammatory cytokines, such as tocilizumab, an anti-interleukin 6 agent, are being tried with encouraging results. Ultimately a protective vaccine will be the best response for controlling the COVID-19 pandemic."}

LitCovid-PD-MONDO

LitCovid-PD-CLO

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T1","span":{"begin":133,"end":136},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T2","span":{"begin":270,"end":277},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"},{"id":"T3","span":{"begin":405,"end":408},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T4","span":{"begin":513,"end":520},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"},{"id":"T5","span":{"begin":524,"end":530},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T6","span":{"begin":607,"end":612},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"},{"id":"T7","span":{"begin":686,"end":687},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T8","span":{"begin":945,"end":951},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"},{"id":"T9","span":{"begin":1112,"end":1115},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T10","span":{"begin":1491,"end":1504},"obj":"http://purl.obolibrary.org/obo/PR_000001393"},{"id":"T11","span":{"begin":1565,"end":1566},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"COVID-19 Comes 40 Years After AIDS - Any Lesson?\nThe pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has hit health-care systems and societies in an unprecedented manner. In 1981, the first cases of AIDS were reported and wide diagnostic testing helped to characterize high-risk groups and the global burden of the epidemic. With Coronavirus Disease (COVID)-19, everything has happened too fast and both cases and fatalities are huge but still uncertain in most places. Diagnostic testing of active and past SARS-CoV-2 infections needs to expand rapidly, ideally using rapid tests. COVID-19 deaths are highly concentrated in the elderly population, with a large proportion of fatalities being \"with\" rather than \"by\" SARS-CoV-2 infection. They are often the result of inadequate health care due to overwhelming demands. To date, there is no specific therapy for SARS-CoV-2 infection. Several antivirals are being tested clinically, including remdesivir, at this time the most promising. For others such as lopinavir/ritonavir, neither significant virological nor clinical benefit has been shown. Given the characteristic pulmonary cytokine storm underlying the pathogenic mechanism of severe COVID-19 pneumonia and acute respiratory distress, antiinflammatory agents are being investigated. The benefit of orticosteroids, hydroxychloroquine, etc., is limited. Monoclonal antibodies targeting different pro-inflammatory cytokines, such as tocilizumab, an anti-interleukin 6 agent, are being tried with encouraging results. Ultimately a protective vaccine will be the best response for controlling the COVID-19 pandemic."}

LitCovid-PD-CHEBI

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T1","span":{"begin":924,"end":934},"obj":"Chemical"},{"id":"T2","span":{"begin":974,"end":984},"obj":"Chemical"},{"id":"T3","span":{"begin":1038,"end":1057},"obj":"Chemical"},{"id":"T4","span":{"begin":1038,"end":1047},"obj":"Chemical"},{"id":"T5","span":{"begin":1048,"end":1057},"obj":"Chemical"},{"id":"T6","span":{"begin":1275,"end":1298},"obj":"Chemical"},{"id":"T7","span":{"begin":1354,"end":1372},"obj":"Chemical"},{"id":"T8","span":{"begin":1470,"end":1481},"obj":"Chemical"}],"attributes":[{"id":"A1","pred":"chebi_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/CHEBI_22587"},{"id":"A2","pred":"chebi_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/CHEBI_145994"},{"id":"A3","pred":"chebi_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/CHEBI_145924"},{"id":"A4","pred":"chebi_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/CHEBI_31781"},{"id":"A5","pred":"chebi_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"},{"id":"A6","pred":"chebi_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/CHEBI_67079"},{"id":"A7","pred":"chebi_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/CHEBI_5801"},{"id":"A8","pred":"chebi_id","subj":"T8","obj":"http://purl.obolibrary.org/obo/CHEBI_64360"}],"text":"COVID-19 Comes 40 Years After AIDS - Any Lesson?\nThe pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has hit health-care systems and societies in an unprecedented manner. In 1981, the first cases of AIDS were reported and wide diagnostic testing helped to characterize high-risk groups and the global burden of the epidemic. With Coronavirus Disease (COVID)-19, everything has happened too fast and both cases and fatalities are huge but still uncertain in most places. Diagnostic testing of active and past SARS-CoV-2 infections needs to expand rapidly, ideally using rapid tests. COVID-19 deaths are highly concentrated in the elderly population, with a large proportion of fatalities being \"with\" rather than \"by\" SARS-CoV-2 infection. They are often the result of inadequate health care due to overwhelming demands. To date, there is no specific therapy for SARS-CoV-2 infection. Several antivirals are being tested clinically, including remdesivir, at this time the most promising. For others such as lopinavir/ritonavir, neither significant virological nor clinical benefit has been shown. Given the characteristic pulmonary cytokine storm underlying the pathogenic mechanism of severe COVID-19 pneumonia and acute respiratory distress, antiinflammatory agents are being investigated. The benefit of orticosteroids, hydroxychloroquine, etc., is limited. Monoclonal antibodies targeting different pro-inflammatory cytokines, such as tocilizumab, an anti-interleukin 6 agent, are being tried with encouraging results. Ultimately a protective vaccine will be the best response for controlling the COVID-19 pandemic."}

LitCovid-PD-HP

{"project":"LitCovid-PD-HP","denotations":[{"id":"T1","span":{"begin":1163,"end":1177},"obj":"Phenotype"},{"id":"T2","span":{"begin":1233,"end":1242},"obj":"Phenotype"},{"id":"T3","span":{"begin":1253,"end":1273},"obj":"Phenotype"}],"attributes":[{"id":"A1","pred":"hp_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/HP_0033041"},{"id":"A2","pred":"hp_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/HP_0002090"},{"id":"A3","pred":"hp_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/HP_0002098"}],"text":"COVID-19 Comes 40 Years After AIDS - Any Lesson?\nThe pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has hit health-care systems and societies in an unprecedented manner. In 1981, the first cases of AIDS were reported and wide diagnostic testing helped to characterize high-risk groups and the global burden of the epidemic. With Coronavirus Disease (COVID)-19, everything has happened too fast and both cases and fatalities are huge but still uncertain in most places. Diagnostic testing of active and past SARS-CoV-2 infections needs to expand rapidly, ideally using rapid tests. COVID-19 deaths are highly concentrated in the elderly population, with a large proportion of fatalities being \"with\" rather than \"by\" SARS-CoV-2 infection. They are often the result of inadequate health care due to overwhelming demands. To date, there is no specific therapy for SARS-CoV-2 infection. Several antivirals are being tested clinically, including remdesivir, at this time the most promising. For others such as lopinavir/ritonavir, neither significant virological nor clinical benefit has been shown. Given the characteristic pulmonary cytokine storm underlying the pathogenic mechanism of severe COVID-19 pneumonia and acute respiratory distress, antiinflammatory agents are being investigated. The benefit of orticosteroids, hydroxychloroquine, etc., is limited. Monoclonal antibodies targeting different pro-inflammatory cytokines, such as tocilizumab, an anti-interleukin 6 agent, are being tried with encouraging results. Ultimately a protective vaccine will be the best response for controlling the COVID-19 pandemic."}

LitCovid-PubTator

LitCovid-sentences

{"project":"LitCovid-sentences","denotations":[{"id":"T1","span":{"begin":0,"end":48},"obj":"Sentence"},{"id":"T2","span":{"begin":49,"end":202},"obj":"Sentence"},{"id":"T3","span":{"begin":203,"end":356},"obj":"Sentence"},{"id":"T4","span":{"begin":357,"end":501},"obj":"Sentence"},{"id":"T5","span":{"begin":502,"end":613},"obj":"Sentence"},{"id":"T6","span":{"begin":614,"end":770},"obj":"Sentence"},{"id":"T7","span":{"begin":771,"end":851},"obj":"Sentence"},{"id":"T8","span":{"begin":852,"end":915},"obj":"Sentence"},{"id":"T9","span":{"begin":916,"end":1018},"obj":"Sentence"},{"id":"T10","span":{"begin":1019,"end":1127},"obj":"Sentence"},{"id":"T11","span":{"begin":1128,"end":1322},"obj":"Sentence"},{"id":"T12","span":{"begin":1323,"end":1391},"obj":"Sentence"},{"id":"T13","span":{"begin":1392,"end":1553},"obj":"Sentence"},{"id":"T14","span":{"begin":1554,"end":1650},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"COVID-19 Comes 40 Years After AIDS - Any Lesson?\nThe pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has hit health-care systems and societies in an unprecedented manner. In 1981, the first cases of AIDS were reported and wide diagnostic testing helped to characterize high-risk groups and the global burden of the epidemic. With Coronavirus Disease (COVID)-19, everything has happened too fast and both cases and fatalities are huge but still uncertain in most places. Diagnostic testing of active and past SARS-CoV-2 infections needs to expand rapidly, ideally using rapid tests. COVID-19 deaths are highly concentrated in the elderly population, with a large proportion of fatalities being \"with\" rather than \"by\" SARS-CoV-2 infection. They are often the result of inadequate health care due to overwhelming demands. To date, there is no specific therapy for SARS-CoV-2 infection. Several antivirals are being tested clinically, including remdesivir, at this time the most promising. For others such as lopinavir/ritonavir, neither significant virological nor clinical benefit has been shown. Given the characteristic pulmonary cytokine storm underlying the pathogenic mechanism of severe COVID-19 pneumonia and acute respiratory distress, antiinflammatory agents are being investigated. The benefit of orticosteroids, hydroxychloroquine, etc., is limited. Monoclonal antibodies targeting different pro-inflammatory cytokines, such as tocilizumab, an anti-interleukin 6 agent, are being tried with encouraging results. Ultimately a protective vaccine will be the best response for controlling the COVID-19 pandemic."}

LitCovid-OGER-BB

{"project":"LitCovid-OGER-BB","denotations":[{"id":"T1","span":{"begin":0,"end":8},"obj":"SP_7"},{"id":"T2","span":{"begin":72,"end":84},"obj":"SP_7"},{"id":"T3","span":{"begin":85,"end":96},"obj":"SP_7;UBERON:0001004"},{"id":"T4","span":{"begin":97,"end":119},"obj":"SP_7"},{"id":"T5","span":{"begin":121,"end":131},"obj":"SP_7"},{"id":"T6","span":{"begin":362,"end":373},"obj":"NCBITaxon:11118"},{"id":"T7","span":{"begin":540,"end":550},"obj":"SP_7"},{"id":"T8","span":{"begin":614,"end":622},"obj":"SP_7"},{"id":"T9","span":{"begin":623,"end":629},"obj":"GO:0016265"},{"id":"T10","span":{"begin":749,"end":759},"obj":"SP_7"},{"id":"T11","span":{"begin":894,"end":904},"obj":"SP_7"},{"id":"T12","span":{"begin":974,"end":984},"obj":"DG_28"},{"id":"T13","span":{"begin":1038,"end":1047},"obj":"DG_23"},{"id":"T14","span":{"begin":1048,"end":1057},"obj":"DG_30"},{"id":"T15","span":{"begin":1153,"end":1162},"obj":"UBERON:0002048"},{"id":"T16","span":{"begin":1224,"end":1232},"obj":"SP_7"},{"id":"T17","span":{"begin":1253,"end":1264},"obj":"UBERON:0001004"},{"id":"T18","span":{"begin":1292,"end":1298},"obj":"CHEBI:67079;CHEBI:67079"},{"id":"T19","span":{"begin":1354,"end":1372},"obj":"CHEBI:5801;DG_20;CHEBI:5801"},{"id":"T20","span":{"begin":1403,"end":1413},"obj":"GO:0042571"},{"id":"T21","span":{"begin":1470,"end":1481},"obj":"DG_35"},{"id":"T22","span":{"begin":1491,"end":1504},"obj":"PR:000001393"},{"id":"T23","span":{"begin":1616,"end":1627},"obj":"GO:0065007"},{"id":"T24","span":{"begin":1632,"end":1640},"obj":"SP_7"}],"namespaces":[{"prefix":"NCBITaxon","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"}],"text":"COVID-19 Comes 40 Years After AIDS - Any Lesson?\nThe pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has hit health-care systems and societies in an unprecedented manner. In 1981, the first cases of AIDS were reported and wide diagnostic testing helped to characterize high-risk groups and the global burden of the epidemic. With Coronavirus Disease (COVID)-19, everything has happened too fast and both cases and fatalities are huge but still uncertain in most places. Diagnostic testing of active and past SARS-CoV-2 infections needs to expand rapidly, ideally using rapid tests. COVID-19 deaths are highly concentrated in the elderly population, with a large proportion of fatalities being \"with\" rather than \"by\" SARS-CoV-2 infection. They are often the result of inadequate health care due to overwhelming demands. To date, there is no specific therapy for SARS-CoV-2 infection. Several antivirals are being tested clinically, including remdesivir, at this time the most promising. For others such as lopinavir/ritonavir, neither significant virological nor clinical benefit has been shown. Given the characteristic pulmonary cytokine storm underlying the pathogenic mechanism of severe COVID-19 pneumonia and acute respiratory distress, antiinflammatory agents are being investigated. The benefit of orticosteroids, hydroxychloroquine, etc., is limited. Monoclonal antibodies targeting different pro-inflammatory cytokines, such as tocilizumab, an anti-interleukin 6 agent, are being tried with encouraging results. Ultimately a protective vaccine will be the best response for controlling the COVID-19 pandemic."}

hydroxychloroquine

{"project":"hydroxychloroquine","denotations":[{"id":"T1","span":{"begin":1163,"end":1177},"obj":"Phenotype"},{"id":"T2","span":{"begin":1233,"end":1242},"obj":"Phenotype"},{"id":"T3","span":{"begin":1253,"end":1273},"obj":"Phenotype"}],"attributes":[{"id":"A1","pred":"hp_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/HP_0033041"},{"id":"A2","pred":"hp_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/HP_0002090"},{"id":"A3","pred":"hp_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/HP_0002098"}],"text":"COVID-19 Comes 40 Years After AIDS - Any Lesson?\nThe pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has hit health-care systems and societies in an unprecedented manner. In 1981, the first cases of AIDS were reported and wide diagnostic testing helped to characterize high-risk groups and the global burden of the epidemic. With Coronavirus Disease (COVID)-19, everything has happened too fast and both cases and fatalities are huge but still uncertain in most places. Diagnostic testing of active and past SARS-CoV-2 infections needs to expand rapidly, ideally using rapid tests. COVID-19 deaths are highly concentrated in the elderly population, with a large proportion of fatalities being \"with\" rather than \"by\" SARS-CoV-2 infection. They are often the result of inadequate health care due to overwhelming demands. To date, there is no specific therapy for SARS-CoV-2 infection. Several antivirals are being tested clinically, including remdesivir, at this time the most promising. For others such as lopinavir/ritonavir, neither significant virological nor clinical benefit has been shown. Given the characteristic pulmonary cytokine storm underlying the pathogenic mechanism of severe COVID-19 pneumonia and acute respiratory distress, antiinflammatory agents are being investigated. The benefit of orticosteroids, hydroxychloroquine, etc., is limited. Monoclonal antibodies targeting different pro-inflammatory cytokines, such as tocilizumab, an anti-interleukin 6 agent, are being tried with encouraging results. Ultimately a protective vaccine will be the best response for controlling the COVID-19 pandemic."}

Inflammaging

{"project":"Inflammaging","denotations":[{"id":"T1","span":{"begin":0,"end":48},"obj":"Sentence"},{"id":"T2","span":{"begin":49,"end":202},"obj":"Sentence"},{"id":"T3","span":{"begin":203,"end":356},"obj":"Sentence"},{"id":"T4","span":{"begin":357,"end":501},"obj":"Sentence"},{"id":"T5","span":{"begin":502,"end":613},"obj":"Sentence"},{"id":"T6","span":{"begin":614,"end":770},"obj":"Sentence"},{"id":"T7","span":{"begin":771,"end":851},"obj":"Sentence"},{"id":"T8","span":{"begin":852,"end":915},"obj":"Sentence"},{"id":"T9","span":{"begin":916,"end":1018},"obj":"Sentence"},{"id":"T10","span":{"begin":1019,"end":1127},"obj":"Sentence"},{"id":"T11","span":{"begin":1128,"end":1322},"obj":"Sentence"},{"id":"T12","span":{"begin":1323,"end":1391},"obj":"Sentence"},{"id":"T13","span":{"begin":1392,"end":1553},"obj":"Sentence"},{"id":"T14","span":{"begin":1554,"end":1650},"obj":"Sentence"},{"id":"T1","span":{"begin":0,"end":48},"obj":"Sentence"},{"id":"T2","span":{"begin":49,"end":202},"obj":"Sentence"},{"id":"T3","span":{"begin":203,"end":356},"obj":"Sentence"},{"id":"T4","span":{"begin":357,"end":501},"obj":"Sentence"},{"id":"T5","span":{"begin":502,"end":613},"obj":"Sentence"},{"id":"T6","span":{"begin":614,"end":770},"obj":"Sentence"},{"id":"T7","span":{"begin":771,"end":851},"obj":"Sentence"},{"id":"T8","span":{"begin":852,"end":915},"obj":"Sentence"},{"id":"T9","span":{"begin":916,"end":1018},"obj":"Sentence"},{"id":"T10","span":{"begin":1019,"end":1127},"obj":"Sentence"},{"id":"T11","span":{"begin":1128,"end":1322},"obj":"Sentence"},{"id":"T12","span":{"begin":1323,"end":1391},"obj":"Sentence"},{"id":"T13","span":{"begin":1392,"end":1553},"obj":"Sentence"},{"id":"T14","span":{"begin":1554,"end":1650},"obj":"Sentence"}],"text":"COVID-19 Comes 40 Years After AIDS - Any Lesson?\nThe pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has hit health-care systems and societies in an unprecedented manner. In 1981, the first cases of AIDS were reported and wide diagnostic testing helped to characterize high-risk groups and the global burden of the epidemic. With Coronavirus Disease (COVID)-19, everything has happened too fast and both cases and fatalities are huge but still uncertain in most places. Diagnostic testing of active and past SARS-CoV-2 infections needs to expand rapidly, ideally using rapid tests. COVID-19 deaths are highly concentrated in the elderly population, with a large proportion of fatalities being \"with\" rather than \"by\" SARS-CoV-2 infection. They are often the result of inadequate health care due to overwhelming demands. To date, there is no specific therapy for SARS-CoV-2 infection. Several antivirals are being tested clinically, including remdesivir, at this time the most promising. For others such as lopinavir/ritonavir, neither significant virological nor clinical benefit has been shown. Given the characteristic pulmonary cytokine storm underlying the pathogenic mechanism of severe COVID-19 pneumonia and acute respiratory distress, antiinflammatory agents are being investigated. The benefit of orticosteroids, hydroxychloroquine, etc., is limited. Monoclonal antibodies targeting different pro-inflammatory cytokines, such as tocilizumab, an anti-interleukin 6 agent, are being tried with encouraging results. Ultimately a protective vaccine will be the best response for controlling the COVID-19 pandemic."}